PERKIRAAN KADAR FENITOIN DALAM DARAH DAN HASIL TERAPI PASIEN EPILEPSI DI RSUD SLEMAN YOGYAKARTA

• Main Authors: , SATRIO WIBOWO RAHMATULLAH, , Prof. Dr. Lukman Hakim, M. Sc., Apt.
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2013
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/124288/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=64408
• Institution: Universitas Gadjah Mada

Medicine with a narrow therapeutic range requires accurate individual dose, monitoring, and rigorous assessment of the patient to maintain the safety and the goodness of the patient. It is because small changes in systemic concentrations can cause significant changes in the pharmacodynamic response, such as subtherapeutic or toxic. Phenytoin is a medicine belonging to the class of narrow therapy range that is widely used in patients with epilepsy. Phenytoin complies non-linear pharmacokinetics with a slight change in dosage, it can easily reach the toxic concentrations. This study aims to determine the relationship between dose and phenytoin levels in the blood and outcome clinic in the patients with epilepsy seen from the duration of seizure-free at the Local Hospital of Sleman Yogyakarta. This study was a descriptive observational study. The sampling method used purposive sampling. The data was collected retrospectively on epilepsy patients with the phenytoin treatment both inpatient and outpatient in the period of January 2010-December 2012, male and female who were routinely controlled for at least 6 consecutive months. Outcome clinic was observed through the duration of the seizure-free and devided into 2, ie < 6 months (unfavorable outcome), and � 6 months (a good outcome). Seen by sex, male have a greater percentage than female (53,6%: 46,4%). Estimated blood levels of phenytoin in the average 5,30±4,03 mg/L. Results therapy are assessed based on the duration of seizure free showed that in the group of patients who received monotherapy as much as 71,83% gives good results, and 28,17% did not give good therapeutic results. While in the group of patients with a 50% combination therapy provides better therapeutic results and 50% gave no good therapeutic results.